Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis.

Authors:
Kouwenberg CV; Koopman-Kalinina Ayuso V; de Boer JH.

Journal:
Acta Ophthalmol

Publication Year: 2021

DOI:
10.1111/aos.15012

PMCID:
PMC9290889

PMID:
34532967

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Acta Ophthalmol

Abbreviation: Acta Ophthalmol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Ophthalmology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Age-related macular degeneration and myeloproliferative neoplasms - A common pathway.
Liisborg C. (2022) - Transparency Score: 1/6
Air versus fluorinated gas tamponades in pars plana vitrectomy treatment for primary rhegmatogenous…
Govers BM; Lamers MPM; Klevering BJ and 1 more (2022) - Transparency Score: 2/6
Antenatal and neonatal factors and morphology of the optic nerve head in the Northern Finland birth…
Pitkänen J; Leiviskä I; Liinamaa J and 1 more (2022) - Transparency Score: 3/6
A prognostic classification system for uveal melanoma based on a combination of patient age and sex…
Gill VT; Sabazade S; Herrspiegel C and 9 more (2022) - Transparency Score: 2/6
Automated artificial intelligence-based system for clinical follow-up of patients with age-related …
Potapenko I; Thiesson B; Kristensen M and 5 more (2022) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:

"This work was financially supported by AbbVie B.V., Hoofddorp, The Netherlands, (grant no.: SA‐002407). The sponsor had no role in the design or conduct of this research."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025